NCT01968382View on ClinicalTrials.gov

Safety and Efficacy of IMM 124-E for Patients With Severe Alcoholic Hepatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

December 22, 2018

Study Completion Date

December 22, 2018

Conditions
Hepatitis, Alcoholic
Interventions
DRUG

IMM 124-E (Hyperimmune Bovine Colostrum)

Hyper-immune bovine colostrum enriched with anti-LPS antibodies and which has been designated by Immuron as IMM-124E.

DRUG

Placebo (High protein milk powder)

Subjects will receive a total of 4 sachets (2 in the morning and 2 in the evening) daily

Trial Locations (3)

23298

Virginia Commonwealth University, Richmond

46202

Indiana University, Indianapolis

55905

Mayo Clinic, Rochester

Sponsors

Collaborators (1)

Immuron Ltd.
All Listed Sponsors
collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

collaborator

Immuron Ltd.

INDUSTRY

lead

Virginia Commonwealth University

OTHER

NCT01968382 - Safety and Efficacy of IMM 124-E for Patients With Severe Alcoholic Hepatitis | Biotech Hunter | Biotech Hunter